2696 (2696) Fair Value & Analysis
Healthcare · Market cap HK$37.6B
Fair value as of: Jul 2, 2026
From 24 valuation models · updated today
Share price +17.1% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$49.60 – HK$88.70 · fair‑value band HK$35.79 – HK$77.05 · the HK$68.70 price screens above the HK$57.90 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
2696 (2696) currently trades at HK$68.70, while our model-based Fair Value estimate is HK$57.90 — implying the stock looks roughly 15.7% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, 2696 generated revenue of HK$6.7B at a net margin of 12.4%. Revenue grew 29.2% year over year. It earns a return on equity of 23.7%. Net debt stands at HK$2.8B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
2696 reported revenue of HK$6.7B in FY2025 versus HK$1.7B in FY2021, a compound +41.1%/yr. Reported net income was HK$806M in FY2025.
Is 2696 fairly valued? → Check now
Recent news
- Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injec
- Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with HLX22
- Shanghai Henlius Biotech (SEHK:2696) Valuation Check As HANBEIYOU Wins Key China Approval
- Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of E-688/HLX316, a First-in-Class B7-H3-Targeted Sialidase f
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 2696 (2696) undervalued?
What is the fair value of 2696?
What is the quality score of 2696?
What is the revenue of 2696 (2696)?
What is the net profit margin of 2696?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.